Chronic Kidney Disease: Staging, Complications, and Renoprotective Therapy

Chronic kidney disease (CKD) is defined by persistent abnormalities of kidney function or structure that have consequences for health [1]. The diagnosis requires evidence of kidney damage or decreased kidney function lasting more than 3 months. [KEY_CONCEPT] CKD represents a progressive decline in excretory kidney function with effects on body homeostasis and is tightly associated with accelerated cardiovascular disease, severe infections, and premature death [1].

KDIGO CKD Staging System:

[HIGH_YIELD] CKD affects approximately 10-15% of adults worldwide, with diabetes mellitus and hypertension being the leading causes. The condition frequently relates to sequential injuries accumulating over the life course or concomitant risk factors rather than a single cause [1]. Early detection and intervention are crucial as kidney failure without access to kidney replacement therapy is fatal.

[CLINICAL_PEARL] The shared pathomechanism of CKD progression involves irreversible loss of kidney cells or nephrons together with hemodynamic and metabolic overload of remaining functional units [1].

Early-stage CKD is often asymptomatic, making screening essential for high-risk populations. Symptoms typically develop when eGFR falls below 30 mL/min/1.73m² (Stage 4-5).

Clinical Manifestations by System:

• Cardiovascular: Hypertension, left ventricular hypertrophy, accelerated atherosclerosis • Metabolic: Metabolic acidosis, hyperkalemia, hyperphosphatemia, hypocalcemia • Hematologic: Anemia due to decreased erythropoietin production • Bone: Secondary hyperparathyroidism, renal osteodystrophy • Fluid/Electrolyte: Volume overload, sodium retention, metabolic bone disease • Uremic: Uremic toxin accumulation causing nausea, vomiting, altered mental status

Major Risk Factors:

1. Primary kidney diseases: Diabetic nephropathy, glomerulonephritis, polycystic kidney disease
2. Systemic diseases: Diabetes mellitus, hypertension, autoimmune diseases
3. Demographics: Advanced age, family history, African American ethnicity
4. Modifiable factors: Obesity, smoking, NSAIDs use, nephrotoxic medications

[HIGH_YIELD] Diabetic nephropathy accounts for approximately 40% of incident ESRD cases, while hypertensive nephrosclerosis accounts for about 25%.

[CLINICAL_PEARL] Patients may remain asymptomatic until significant kidney function loss occurs, emphasizing the importance of routine screening in high-risk populations with annual eGFR and albuminuria assessment.

Diagnostic Criteria for CKD (≥3 months duration):

✓ eGFR <60 mL/min/1.73m² OR ✓ Markers of kidney damage:

• Albuminuria (ACR ≥30 mg/g)
• Urine sediment abnormalities
• Electrolyte abnormalities due to tubular disorders
• Histological abnormalities
• Structural abnormalities on imaging
• History of kidney transplantation

Laboratory Assessment Algorithm:

Initial Assessment ├── Serum creatinine → Calculate eGFR (CKD-EPI equation) ├── Urine albumin-to-creatinine ratio (ACR) ├── Urinalysis with microscopy ├── Complete metabolic panel └── CBC with differential

↓

Confirm CKD (repeat labs in 3 months) ├── Persistent eGFR <60 OR ├── Persistent albuminuria ≥30 mg/g OR └── Persistent structural abnormalities

↓

Staging & Risk Stratification ├── GFR category (G1-G5) ├── Albuminuria category (A1-A3) └── Assess progression risk

[KEY_CONCEPT] Risk stratification combines GFR and albuminuria categories to predict outcomes. Higher albuminuria categories (A2, A3) significantly increase cardiovascular and kidney failure risk across all GFR categories.

Additional Diagnostic Studies:

• Kidney imaging: Ultrasound to assess size, echogenicity, obstruction • Kidney biopsy: Consider if unclear etiology, rapidly progressive decline, or treatment decisions needed • Cardiovascular assessment: ECG, echocardiogram for patients with advanced CKD

[HIGH_YIELD] The CKD-EPI equation is preferred for eGFR calculation over the MDRD equation due to improved accuracy, especially at higher GFR levels.

Comprehensive CKD Management Strategy:

1. Blood Pressure Control [3]

• Target: <130/80 mmHg for most CKD patients • First-line therapy: ACE inhibitors or ARBs, especially with albuminuria • Second-line: Long-acting dihydropyridine calcium channel blockers • Third-line: Thiazide or thiazide-like diuretics

[CLINICAL_PEARL] Dietary sodium restriction (<2g/day) enhances the effectiveness of renin-angiotensin system blockade and improves blood pressure control [3].

2. Novel Renoprotective Therapies

SGLT2 Inhibitors - Revolutionary advancement in CKD management:

3. Metabolic Management

• Diabetes control: HbA1c target 6.5-7.5% (individualized) • Lipid management: Statins for cardiovascular protection • Bone-mineral disorders: Phosphate binders, vitamin D analogs, calcimimetics • Anemia: ESA therapy when Hgb <10 g/dL with iron deficiency correction

4. Lifestyle Modifications

• Dietary protein: 0.8 g/kg/day (avoid excessive restriction) • Smoking cessation: Critical for slowing progression • Weight management: BMI 20-25 kg/m² • Regular exercise: Adapted to functional capacity

[HIGH_YIELD] SGLT2 inhibitors provide renoprotection independent of diabetes status and should be considered in CKD patients with eGFR ≥20 mL/min/1.73m² and significant albuminuria.

Major CKD Complications:

Cardiovascular Disease - Leading cause of morbidity and mortality • Accelerated atherosclerosis and coronary artery disease • Left ventricular hypertrophy and heart failure • Sudden cardiac death risk increases with declining eGFR

Mineral and Bone Disorders (CKD-MBD) • Secondary hyperparathyroidism (PTH >2x upper normal) • Hyperphosphatemia (phosphorus >4.6 mg/dL) • Vitamin D deficiency and resistance • Renal osteodystrophy and increased fracture risk

Anemia of CKD • Typically develops when eGFR <30 mL/min/1.73m² • Primarily due to decreased erythropoietin production • Associated with reduced quality of life and increased mortality

Progressive Kidney Function Decline

Monitoring Schedule:

Stage 1-2 (eGFR >60) ├── Annual eGFR and ACR └── Cardiovascular risk assessment

Stage 3a (eGFR 45-59) ├── Every 6 months: eGFR, ACR ├── Annual: CBC, CMP, PTH └── Nephrology referral consideration

Stage 3b-4 (eGFR 15-44) ├── Every 3-6 months: eGFR, ACR ├── Every 6 months: CBC, CMP, PTH, 25(OH)D ├── Nephrology referral (mandatory) └── RRT preparation discussions

Stage 5 (eGFR <15) ├── Monthly monitoring ├── RRT initiation planning └── Transplant evaluation

Key Monitoring Parameters:

• Progression markers: eGFR decline >3 mL/min/1.73m²/year or >5 mL/min/1.73m²/year if eGFR >60 • Metabolic complications: Electrolytes, acid-base status, mineral metabolism • Cardiovascular risk: Blood pressure, lipids, diabetes control • Nutritional status: Protein-energy wasting, phosphorus, calcium

[HIGH_YIELD] Nephrology referral should occur by Stage 4 CKD (eGFR <30) to optimize management and prepare for renal replacement therapy.

[CLINICAL_PEARL] Patients with rapidly progressive CKD (>3 mL/min/1.73m²/year decline) require urgent nephrology evaluation regardless of current eGFR stage.

Prognostic Factors in CKD:

Primary Predictors of Progression:

1. Albuminuria severity: Strongest predictor of kidney failure risk
2. eGFR decline rate: >3 mL/min/1.73m²/year indicates rapid progression
3. Underlying etiology: Diabetic nephropathy vs. other causes
4. Blood pressure control: Uncontrolled HTN accelerates decline
5. Cardiovascular comorbidities: Increase overall mortality risk

Kidney Failure Risk by Stage:

Renal Replacement Therapy Options:

Kidney Transplantation - Preferred treatment • Living donor: Best long-term outcomes • Deceased donor: Standard option with waiting times • Preemptive transplant: Before dialysis initiation when possible

Dialysis Modalities: • Hemodialysis: 3x/week in-center or home options • Peritoneal dialysis: Continuous ambulatory or automated [6] • Conservative management: Symptom-focused care without RRT

[KEY_CONCEPT] Cardiovascular mortality remains the leading cause of death in CKD patients, often exceeding kidney failure mortality until advanced stages.

Long-term Outcomes: • 5-year survival: Varies significantly by age, comorbidities, and RRT modality • Transplant recipients: 85-95% 5-year survival with living donor kidneys • Dialysis patients: 40-60% 5-year survival depending on age and comorbidities

[HIGH_YIELD] Early preparation for RRT, including vascular access creation and transplant evaluation, significantly improves outcomes and reduces complications.

[CLINICAL_PEARL] Patients should be informed about all RRT options, including conservative management, to make informed decisions aligned with their values and goals of care.